Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma.
Saved in:
| Title: | Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. |
|---|---|
| Authors: | Gavriatopoulou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. mariagabria@gmail.com., Terpos E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Ntanasis-Stathopoulos I; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Malandrakis P; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Eleutherakis-Papaiakovou E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Papatheodorou A; Department of Medical Research, 251 General Air Force Hospital, Athens, Greece., Kanellias N; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Migkou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Fotiou D; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Dialoupi I; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Roussou M; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Kokkali NA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Kastritis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. |
| Source: | Blood cancer journal [Blood Cancer J] 2020 Mar 02; Vol. 10 (3), pp. 25. Date of Electronic Publication: 2020 Mar 02. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
